Protara Therapeutics (TARA) Liabilities and Shareholders Equity (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $191.9 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 13.86% year-over-year to $191.9 million in Q1 2026; TTM through Mar 2026 was $703.0 million, a 28.81% increase from a year earlier, with the FY2025 full-year figure at $209.5 million, up 15.44% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $191.9 million, down from $209.5 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for TARA reached as high as $209.5 million in Q4 2025 and fell as low as $68.1 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $133.2 million across 5 years, with a median of $144.6 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity plunged 40.46% in 2023 and soared 147.39% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $113.3 million in 2022, then slumped by 30.31% to $79.0 million in 2023, then surged by 129.82% to $181.5 million in 2024, then advanced by 15.44% to $209.5 million in 2025, then retreated by 8.38% to $191.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $191.9 million in Q1 2026, $209.5 million in Q4 2025, and $144.6 million in Q3 2025.